iron-chelating agent
CAS：138-14-7
分子式：C26H52N6O11S
分子量：656.79
纯度：98%
存储：Store at -20°C

Background:

Deferoxamine mesylate is a specific iron-chelating agent [1][2][3]

Deferoxamine mesylate can be used for treating acute iron intoxication. Deferoxamine complexed with iron to form ferrioxamine and then prevented the iron from entering into further chemical reactions. The formed chelate is readily soluble in water and passes easily through the kidney [1].

In Fisher rats transplanted with the 13762NF mammary adenocarcinoma, deferoxamine mesylate reduced rat tumor growth. While deferoxamine mesylate?injections plus a low iron diet caused the greatest inhibitory effect on tumor growth. Deferoxamine mesylate may be a useful chemotherapeutic agent in the treatment of breast cancer [2]. In Sprague-Dawley rats, injected with deferoxamine mesylate (75-90 mg; 300 mg/kg) via the celiac artery before surgery. Deferoxamine mesylate signi?cantly lowered the serum levels of amylase, lipase, and malondialdehyde (MDA) after orthotopic liver autotransplantation. Deferoxamine mesylate also protected pancreatic tissue through up-regulated expression of HIF-1 protein and inhibition of oxidative toxic reactions [3].

参考文献:
[1].Deferoxamine mesylate (Desferal mesylate).? A specific iron-chelating agent for treating acute iron intoxication. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):595-6.
[2].Wang F, Elliott RL, Head JF.? Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res. 1999 Jan-Feb;19(1A):445-50.
[3].Li Y, Zhang PJ, Jin C, et al.? Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats. Transplant Proc. 2011 Jun;43(5):1450-5.